Opinion|Videos|June 26, 2024
Transitioning Patients Back to Community Practices Following CAR T
Members of the panel discuss their criteria for determining when a patient is ready to transition back to community oncologists after they receive CAR T-cell therapy.
Advertisement
Episodes in this series
- Dr. Krishnan: What criteria or thresholds do you use to determine when a patient is ready for transition back to the community oncologist after CAR-T therapy? (e.g. time since infusion, resolution of toxicities, evidence of response)
- Dr. Park: At what point in the patient's recovery course after CAR-T do you think it is ideal for their care to transition back to the community oncologist? What factors influence this timing?
- How much clinical/treatment detail from the CAR-T process at the academic center is typically provided or needed by community providers for optimal long-term monitoring and follow-up of the patient?
Advertisement
Related to this article
Ralph V. Boccia, MD, FACP, noted how designated hospitals and a 24/7 on-call team support emergencies during bispecific step-up dosing.
Ralph V. Boccia, MD, FACP, explained the caregiver’s role in monitoring and reporting during bispecific antibody step-up dosing.
Ralph V. Boccia, MD, FACP, explained who needs REMS certification and which care team members need training to deliver bispecific antibodies.
Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed quadruplet induction, extended maintenance, and when a community clinician should call a myeloma center.
Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed the threshold he will act on in standard-risk disease, and the trial that would make the decision firmer.
In a retrospective analysis, teclistamab produced response rates numerically higher than in MajesTEC-1, with missed doses not compromising outcomes.
Data from the phase 3 OCEAN trial and others support the expanded approval for melflufen in patients with previously treated multiple myeloma.
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Perioperative Durvalumab/Enfortumab Vedotin in MIBC
2
ACS Updates Prostate Cancer Screening Guideline With Risk-Based PSA Intervals
3
Why Caregivers Are Critical During Bispecific Step-Up Dosing
4
Prizlon-cel Earns FDA RMAT and Fast Track Designations in Relapsed LBCL
5